Scott Randall Plotkin, M.D.,Ph.D.
This page shows the publications co-authored by Scott Plotkin and April Eichler.
Brain metastases. Curr Treat Options Neurol. 2008 Jul; 10(4):308-14.
Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. NPJ Precis Oncol. 2017; 1.
Increased perfusion due to vascular normalization improves oxygenation and survival in glioblastoma patients treated with cediranib with or without chemoradiation. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii12.
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):19059-64.
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro Oncol. 2013 Aug; 15(8):1079-87.
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J Neurooncol. 2011 Jun; 103(2):325-32.
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010 Jun 10; 28(17):2817-23.
Use of video to facilitate end-of-life discussions with patients with cancer: a randomized controlled trial. J Clin Oncol. 2010 Jan 10; 28(2):305-10.
Phase I trial of vatalanib (PTK787) in combination with standard radiation and temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):2035.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.